Abbott Laboratories (ABT) financials · rev $44.33B
Lician Pro · $19.99/mo or $149/yrCompare AAPL vs MSFT
Abbott Laboratories (ABT) rev $44.33B.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $44.33B | $41.95B |
| Cost of Revenue | $19.32B | $18.71B |
| Gross Profit | $25.01B | $23.24B |
| Operating Income | $8.05B | $6.83B |
| Net Income | $6.52B | $13.40B |
| EPS (Diluted) | $3.72 | $7.64 |
| Line | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $86.71B | $81.41B |
| Current Assets | $26.00B | $23.66B |
| Cash & Equivalents | $8.52B | $7.62B |
| Inventory | $6.49B | $6.19B |
| PP&E | $11.82B | $10.66B |
| Total Liabilities | $34.58B | $33.75B |
| Current Liabilities | $16.50B | $14.16B |
| Short-term Debt | $3.03B | $1.50B |
| Long-term Debt | $9.90B | $12.63B |
| Total Debt | $12.93B† | $14.13B† |
| Shareholders' Equity | $52.13B | $47.66B |
| Retained Earnings | $49.78B | $47.26B |
† Total Debt: Derived: short-term debt plus long-term debt (no total debt stored).
| Line | FY2025 | FY2024 |
|---|---|---|
| Operating Cash Flow | $9.57B | $8.56B |
| CapEx | $2.17B | $2.21B |
| Investing Cash Flow | -$2.42B | -$2.34B |
| Financing Cash Flow | -$6.31B | -$5.40B |
| Dividends Paid | $4.12B | $3.84B |
| Net Change in Cash | $906.0M | $720.0M |
| Free Cash Flow | $7.39B | $6.35B |
FAQ
What is ABT P/E and revenue?
Abbott Laboratories (ABT) rev $44.33B.
What is ABT revenue?
Abbott Laboratories last cached revenue is $44.33B (FY2025).
Is ABT profitable?
Abbott Laboratories last cached net income is $6.52B (FY2025).
What are ABT total assets?
Abbott Laboratories last cached total assets are $86.71B (FY2025).
What is ABT free cash flow?
Abbott Laboratories last cached free cash flow is $7.39B (FY2025).
Not investment advice. Cached statements, not a live tape.